Login
$AURA
$7.22 +$0.11 (1.55%) Live

Company Executives

Officer Age In this role 2025 pay Source
Amy Elazzouzi
interim principal financial officer
Title from the Form 8-K dated Sep 2, 2026
Not stated Not stated Not reported
Susan Abu-Absi
Chief Operating Officer
Title from the Form 4 dated Sep 1, 2026
Not stated Not stated Not reported
J. Jill Hopkins
Chief Medical Officer and President of Research and Development
61 Since 2023
3 years
$2,188,965
Mark Plavsic
Chief Technology Officer
65 Since 2023
3 years
Not reported
Julie Person
Chief People Officer
Title from the Form 4 dated Sep 1, 2026
Not stated Not stated Not reported
Anthony Gibney
See Remarks
Title from the Form 4 dated Jun 16, 2026
55 Not stated $2,751,226
Conor Kilroy
See Remarks
Title from the Form 4 dated Jul 1, 2026
44 Not stated Not reported
Erica Kratz
Chief Reg. & Quality Officer
Title from the Form 4 dated Sep 1, 2026
Not stated Not stated Not reported
Natalie Holles Also a director
See Remarks
Title from the Form 4 dated May 19, 2026
Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 20, 2026 · updated by the 8-Ks of May 4, 2026 and Jul 8, 2026

Directors
9
serving now
Independent
7 of 8
stated in the proxy; 1 not stated
Average tenure
6.7 years
from year joined
CEO also chairs the board
No
David Johnson
Director Age On board Independent Committees Other public boards 2025 pay Source
David Johnson
61 2021
5 years
Independent
Nominating and Corporate Governance Committee
Zentalis Pharmaceuticals, Inc. $235,331
Elisabet de los Pinos
53 2009
17 years
Not independent None stated None stated Paid as CEO
Natalie Holles Joined Apr 30, 2026
- - - - - Paid as CEO
Giovanni Mariggi
41 2019
7 years
Independent
Audit Committee Compensation Committee · Chair
Fore Biotherapeutics US Inc., Vaderis Therapeutics AG, Curevo Inc., Vicebio Ltd. Not stated
Antony Mattessich
59 2021
5 years
Independent
Audit Committee Nominating and Corporate Governance Committee · Chair
None stated $214,891
Sapna Srivastava
55 2021
5 years
Independent
Audit Committee · Chair
Nuvalent, Inc., Alumis, Inc. Not stated
Teresa Marie Bitetti
63 2025
1 year
Independent
Compensation Committee
Osmol Therapeutics, Inc. $283,562
Jeremy Bender Joined Jul 7, 2026
- - Independent
Compensation Committee Nominating and Corporate Governance Committee
- -
Karan Takhar Leaving at the meeting
Not stated Not stated Independent
Compensation Committee Nominating and Corporate Governance Committee
None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

No related-party transactions disclosed

The proxy filed Apr 20, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support